Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

SAN FRANCISCO, Feb. 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its financial results and pipeline progress for the year ended December 31, 2007.

"In 2007 we continued our track record of milestone achievement to advance development across our entire portfolio, and we are pleased to enter 2008 with an Alzheimer's disease product candidate in confirmatory Phase 3 development," said David T. Hung, M.D., president and chief executive officer of Medivation. "We remain committed to the rapid, efficient development of our novel product candidates for Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer to make them available to people around the world who are increasingly afflicted with these deadly and debilitating diseases for which there are still very few treatment options."

Recent Accomplishments

Alzheimer's Disease

-- Completed a double-blinded, placebo-controlled twelve month extension

of our first pivotal Alzheimer's disease (AD) trial, in which patients

continued to show statistically significant benefits on all five

clinical endpoints studied;

-- Completed a comprehensive Phase 1 clinical development program in the

U.S., which continued to show Dimebon to be safe and well tolerated;

-- Completed a successful end-of-Phase 2 meeting with the U.S. Food and

Drug Administration, which recognized our previously completed AD trial

as pivotal and allowed us to proceed to a confirmatory pivotal Phase 3

trial;

Huntington's Disease

-- In collaboration with the Huntington Study Group, began a randomized,

double-blinded, placebo-controlled Phase 1-2 trial
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... Molecule Sequencing (tSMS™) technology, announced today the closing ... of investment, led by Genomic Diagnostic Technologies, will ... and diagnostic applications. , Founded in March 2013 ... and Bioinformatics Analyst at Helicos BioSciences, SeqLL has ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... November 14, 2008 at 9:00 a.m. Eastern ... ... Inc. (Nasdaq: ALSE ) today reports operational and,financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the ...
... Alternext US: PIP), a biodefense company developing medical,countermeasures ... operational results for the third quarter and nine ... quarter of 2008, PharmAthene recognized revenues of $10.7,million ... of 2007. For the nine,months ended September 30, ...
... Choice, Based on Its Comprehensive,Service Portfolio, MOUNTAIN ... recent,analysis of the pharmaceutical contract manufacturing market, Frost ... the 2008 North,American Frost & Sullivan Customer Service ... in Healthcare Innovation Awards Banquet held in San,Antonio, ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 2Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 3
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... prompts millions of Americans to undertake jaunts into the countryside ... little longer within a century, according to new research. , ... of the United States as summer temperatures linger later into ... Global Ecology and Biogeography . For instance, the paper birch ... of New Hampshire could change color one to three ...
(Date:9/18/2014)... Americans across racial and ethnic groups describe losing ... their day-to-day life, more so than other conditions ... (57% of African-Americans, 49% of non-Hispanic whites, 43% ... which disease or ailment is the worst that ... African-Americans followed by AIDS/HIV. Hispanics and Asians ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... by Vanderbilt,s Roger Cone, Ph.D., have discovered a new member ... and the regulation of body weight. The gene is the ... been identified previously in humans. One helps determine skin and ... in obesity and diabetes. The new gene, called agrp2, has ...
... -- Curcumin, a chemical that gives curry its zing, ... an advanced form of a condition known as fatty ... Curcurmin is contained in turmeric, a plant used by ... years. SLU,s recent study highlights its potential in countering ...
... London today signed an official agreement to jointly establish ... by Prime Minister Lee Hsien Loong at the National ... for the school is "Imperial College London-Nanyang Technological University ... ICNMS will be positioned to meet Singapore,s healthcare demands ...
Cached Biology News:Newly discovered gene enables fish to 'disappear' 2Spice in curry could prevent liver damage 2Imperial and NTU's new medical school aspires to be global health care role model 2Imperial and NTU's new medical school aspires to be global health care role model 3Imperial and NTU's new medical school aspires to be global health care role model 4
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: